Breaking AI & Tech News Analyzed

The Medical Breakthrough Scientists have achieved what was once considered impossible: developing a drug that targets pancreatic cancer, a disease long deemed 'undruggable' due to its complex biology and resistance to conventional treatments. The new daily pill, daraxonrasib, has shown remarkable efficacy in clinical trials, doubling survival time for patients diagnosed with this aggressive form of cancer. The Clinical Trial Results Recent clinical trials have demonstrated that daraxonrasib can significantly extend the lives of pancreatic cancer patients. The drug works by targeting specific genetic mutations that drive cancer growth, a approach that has eluded researchers for decades. Patients receiving the treatment showed a median survival rate that was double that of the control group, representing a unprecedented improvement in outcomes for this deadly disease. The Implications for Cancer Treatment This breakthrough marks a paradigm shift in how we approach pancreatic cancer treatment. Historically, patients have faced grim prognoses with limited therapeutic options. The success of daraxonrasib opens new avenues for targeting previously 'undruggable' cancers and may inspire similar approaches for other difficult-to-treat malignancies. The pharmaceutical industry is likely to accelerate investment in similar targeted therapies, potentially transforming the treatment landscape for multiple cancer types. The Future of Pancreatic Cancer Treatment With this promising development on the horizon, researchers are now focusing on optimizing daraxonrasib for broader patient populations and exploring combination therapies that could further improve outcomes. The drug's success may also lead to earlier detection methods and personalized treatment approaches based on individual genetic profiles. As this treatment moves toward regulatory approval and potential market availability, patients and healthcare providers alike are cautiously optimistic about a new era in pancreatic cancer care.

Colette Delawalla, founder of Stand Up for Science, warned that the OMB’s draft rule would turn $1.5 trillion of federal research money into a political slush fund, effectively dismantling the U.S. science ecosystem.The Proposed OMB Rule Threatening Federal Research GrantsThe Office of Management and Budget, led by Russ Vought, released a 411‑page proposal on 29 May that would require all discretionary research awards to “demonstrably advance the president’s policy priorities” and ban collaborations deemed to promote “anti‑American values.” The rule would shift grant decision‑making from scientific experts to political appointees.Numbers Behind the Controversy: Potential Losses in Clinical TrialsStand Up for Science estimates that nearly 5,000 of the roughly 10,000 NIH‑funded clinical trials could be halted.Potentially affected studies include > 1,000 cancer trials, hundreds of pediatric, veteran, suicide, heart‑disease, and diabetes trials.More than 31,000 public comments have been submitted to the OMB’s docket as of 13 July.Why the Rule Could Undermine the U.S. Science EcosystemThe rule threatens not only high‑profile research but also everyday innovations funded by federal grants, from wheelchair technology to veterans’ housing. By politicizing grant approvals, it could discourage international collaboration, a cornerstone of modern science, and erode public trust in federal research institutions.What Comes Next: Legal Battles and Congressional PushbackStand Up for Science is coordinating a legal strategy, having convened about 50 attorneys nationwide. In Congress, only a handful of members, such as Senator Chris Van Hollen, appear fully briefed on the proposal, while others dismiss the concerns as “protesters.” The organization continues to urge public comments before the 13 July deadline and is preparing to challenge the rule in court if it is finalized.

The Allure of Biological Age Tests In the season 5 finale of The Kardashians, the family took a commercially available blood test to discover how fast their bodies were ageing. The reality TV stars were said to be ageing more slowly than most mortals of the same age, with Khloé, then 39, finding she had a biological age of 28. The Science Behind Biological Age Tests Researchers have been devising molecular clocks to estimate biological age for more than a decade. The new method, devised by Vadim Gladyshev from Harvard Medical School and colleagues, not only provides a measure of biological ageing but also a 'time to death'. The Data Analysis Gladyshev's method is based on patterns of gene activity, collected from more than 4,000 people to establish how the patterns relate to age and disease. The researchers believe this method is more sensitive than its predecessors. The Impact Analysis The test could shorten the lengthy clinical trials needed to tell if anti-ageing treatments work. It could also be used to inform age-related policy, adjusting for the reality that some people age differently than their peers. The Prediction However, the author questions the value of such tests, citing concerns about the psychological impact of knowing one's biological age and the potential for self-fulfilling prophecies. The emerging idea is that beliefs about ageing don't just stay in the mind – they can become biologically embodied, influencing physical health, ageing, and longevity.

The Rise of Unregulated Stem Cell Treatments for Autism Autistic children as young as 18 months old are being injected with human stem cells derived from umbilical cords in unapproved, unproven and potentially harmful "treatments" that scientists warn are proliferating across the US under the active encouragement of the US health secretary, Robert F Kennedy Jr. Clinics in Florida, Texas and other states are selling what they bill as "regenerative medicine" to families with autistic children who have intensive care needs. Parents who have taken their children through the process talked about their hopes and fears for a therapy that appears to be gaining ground in the US. The Mechanics of Questionable Stem Cell Procedures The procedure, which can involve the child being sedated with ketamine before receiving intravenous doses of millions of stem cells, costs up to $20,000 for each treatment. Families are often advised to return for regular top-ups. Profoundly stressed parents are being wooed to the clinics with promises that a high-dose infusion of umbilical cord stem cells can lead to dramatic improvements in their children's ability to speak, socialise, or avoid aggressive or self-harming behaviour. Yet there is no scientific evidence that the procedure works – the most comprehensive clinical trial staged so far, a placebo experiment conducted by Duke University, found insignificant benefits for most of the 180 children tested. The US Food and Drug Administration (FDA) directly cautions parents that if they are being offered stem cell treatments outside an approved clinical trial, "you are likely being deceived and offered a product illegally". Financial Impact of the Unregulated Treatment Market The burgeoning market for unproven stem cell treatments represents a significant financial burden on families already dealing with the high costs of autism care. Treatments can cost up to $20,000 per session, with many providers recommending multiple treatments over time. Among the providers is Better Stem, a Miami-based company run by Greice Murphy, which charges $300 for an initial consultation followed by up to $15,000 per infusion. The company claims to be the first in the US offering "legal, compliant access" to stem cell therapies under the "right-to-try" law, despite autism not meeting the legal definition of a terminal illness covered by that legislation. Families like Taylor and her four-year-old son Ollie from Utah are raising funds through donations to cover the $12,500 cost of a single treatment, highlighting the desperate financial sacrifices parents are making for these unproven therapies. Regulatory Erosion and Shifting Healthcare Landscape In his 16 months as the secretary of the Department of Health and Human Services within the Trump administration, Kennedy has undercut established scientific endeavors. He has fired thousands of federal health officials, dismissed longstanding scientific advisers, defunded $31m in autism-related research and attempted to shrink the recommended list of childhood vaccinations. At the same time, largely unnoticed, he has given his backing to alternative health providers moving to fill the gap. Kennedy appeared by video link at the first two annual summits held in San Diego by Autism Health, a leading advocate of stem cell infusions for autistic kids. Those providers include Mike Chan, a Malaysian physician who presented the San Diego summit with a protocol that involves injecting autistic children in the buttocks with high doses of stem cells extracted from slaughtered sheep and rabbits. Kennedy described the organiser of the San Diego summit, Tracy Slepcevic, as a "good friend" and appointed her to his remodelled Autism Coordinating Committee, which guides federally funded autism research. Future Outlook for Autism Treatment Regulation The proliferation of unproven stem cell treatments for autism appears likely to continue, with a new clinical trial planned to involve 120 autistic children in Mexico, a country that has historically taken a looser approach to stem cell regulation than the US. Ed Clay, founder of the Cellular Performance Institute in Tijuana, said the clinical trial would be free to families and fully licensed under the Mexican federal health authority, Cofepris. He claimed his team includes "21 PhD scientists and 42 medical doctors, including PhDs from institutions such as Harvard, Yale, MIT and Stanford". While Clay said the clinical trial could potentially be imported to US sites under full FDA licensing if early results are promising, other stem cell providers operating in this space may not hold such standards. Clay himself acknowledged: "I would say our biggest competitor right now for CPI is the scammer and the many fly-by-night clinics operating in this space." Despite Kennedy's stated desire to prevent a "wild west" of alternative therapies, his administration's actions suggest a continued expansion of unregulated treatments, potentially leaving vulnerable families exposed to financial exploitation and medical risks without scientific validation.

The Lead A new study reveals that apitegromab, a drug promoting muscle growth, could significantly reduce the loss of lean body mass when using popular weight-loss medications like tirzepatide (found in Mounjaro). This breakthrough addresses a significant concern with current weight-loss treatments that cause patients to lose muscle along with fat. The Scientific Breakthrough GLP-1 based weight-loss jabs such as Wegovy and Mounjaro have proven highly effective for people who are overweight or obese, but studies show 25-40% of total weight loss comes from reduction in lean body mass – non-fat components including muscle. This matters because lean body mass is important for physical strength, burns more calories than fat tissue, and is linked to a lower risk of type 2 diabetes. Apitegromab works by blocking myostatin, a protein involved in inhibiting muscle growth. In a small trial, researchers in the US randomly divided 102 participants into two groups: 51 received apitegromab alongside tirzepatide, while the other 51 received a placebo with tirzepatide. The Clinical Trial Results After 24 weeks, the trial revealed that total weight loss was similar between the two groups. However, participants given apitegromab alongside tirzepatide lost on average 1.6kg (3.5lb) of lean mass (14.6% of total weight loss), while those given tirzepatide with a placebo lost an average of 3.5kg of lean mass. This means apitegromab was associated with a 55% greater retention of lean mass relative to placebo. The study had limitations, including that most participants were women and the trial was small and short in duration. However, the number of people experiencing side-effects was similar between the two groups, with most deemed to be mild. The Implications for Weight Loss Treatment Prof Alexander Miras, an obesity expert at Ulster University not involved in the work, described the findings as very important. While GLP-1s have been associated with improved "functionality" – making everyday activities easier – they've also been linked to loss in muscle mass and strength. This new medication may help reduce these effects and improve functionality even further. Prof Naveed Sattar, a cardiometabolic medicine expert at the University of Glasgow, emphasized that larger-scale and longer trials are needed to confirm safety and actual health benefits. In the meantime, he recommended that people prescribed weight-loss drugs should be supported to increase physical activity, which can help maintain muscle mass in a physiological way. The Future of Weight Loss Therapies The findings suggest a promising direction for weight-loss treatments that preserve muscle mass while reducing fat. As the popularity of GLP-1 based medications continues to grow, addressing muscle loss could become an important focus for pharmaceutical companies and healthcare providers. Future research will need to confirm the long-term safety and effectiveness of combining apitegromab with weight-loss medications. If successful, such combinations could become standard practice, potentially improving patient outcomes and quality of life during weight loss journeys.

Cathy Tie, the self‑styled “Biotech Barbie,” used her 30th‑birthday concert at Carnegie Hall as a launchpad for a new gene‑editing company that seeks to eradicate inherited diseases by editing embryos. Backed by high‑profile venture capitalists, her move spotlights a rapidly growing, yet heavily regulated, frontier in human biotechnology.Cathy Tie's Grand Carnegie Hall Birthday and the Birth of a New Gene‑Editing VentureOn a Friday evening in late April 2026, Tie performed Saint‑Saëns’ Piano Concerto No 2 in a pink tulle gown, then turned the spotlight to her entrepreneurial ambition: a startup—initially called Manhattan Project, now operating under Origin Genomics—focused on germline editing to prevent conditions such as cystic fibrosis, Huntington’s disease, and hereditary cancers.Location: Carnegie Hall, New York CityEvent: 30th birthday celebration and public announcement of the ventureGoal: Open, regulator‑approved editing of human embryos for disease preventionFunding Landscape: Billionaire Backers and Emerging Start‑upsSince Tie’s arrival in New York (August 2025), a wave of ultra‑wealthy investors has poured capital into the human‑genetics arena.Preventive launched in October 2025 with a mission to “prevent disease before birth.”Investors include Sam Altman (OpenAI), Oliver Mulherin, and Brian Armstrong (Coinbase CEO).Armstrong coined the term “Gattaca stack,” highlighting a suite of technologies—gene editing, pre‑implantation genetic testing (PGT), and embryo selection—that could become routine.Regulatory Roadblocks and Ethical Storms Around Germline EditingDespite the influx of private money, germline editing for reproductive purposes remains banned in the UK, US, and China. International consensus discourages research that could produce viable babies, citing the irreversible impact on future generations.Current bans prohibit implantation of edited embryos that could develop to term.He Jiankui’s 2018 experiment—editing twins for HIV resistance—resulted in a three‑year prison sentence and a fine of 3 million yuan.China’s recent draft regulations (September 2026) aim to accelerate biotech R&D, hinting at a possible softening of the stance.What Lies Ahead for Human Germline EngineeringTie argues that secrecy will only drive rogue actors underground; she advocates for transparent, regulator‑approved research. The trajectory of the field will likely hinge on three factors:Regulatory evolution: Any relaxation of bans could unlock commercial pathways.Public acceptance: Wider societal dialogue is needed to balance benefits against ethical concerns.Competitive pressure: Billionaire‑backed rivals and state‑driven programs may accelerate breakthroughs, intensifying a “biological arms race.”If these dynamics align, germline editing could move from experimental labs to clinical trials within the next decade, reshaping concepts of disease, inheritance, and even what it means to be human.

The Lead: Moving from 'War' to ManagementThe editorial argues that while a 'final victory' over cancer remains elusive, the recent American Society of Clinical Oncology (ASCO) meeting in Chicago has delivered tangible hope, moving the medical community closer to treating cancer as a manageable chronic condition rather than an immediate death sentence.Breakthroughs at ASCO: From 'Undruggable' Targets to New JabsImmunotherapy & Surgery: New immunotherapy treatments have emerged that could spare bladder cancer patients from invasive and life-changing surgery.Head and Neck Cancer: A novel jab has shown effectiveness against head and neck cancers in clinical trials.The Daraxonrasib Milestone: The most significant development is the drug daraxonrasib, which has successfully targeted the Ras family of molecules—a target previously deemed 'undruggable' since the 1980s.Quantifying the Gains: Survival Metrics and PrognosesThe most striking data comes from the pancreatic cancer trial involving daraxonrasib. Patients in the study lived on average 13 months compared to the standard 6 months, effectively doubling their survival time. This is critical given the grim statistics for pancreatic cancer, where only about 1 in 20 patients survive five years post-diagnosis in the UK.Shifting the Paradigm: From 'War' to Chronic ManagementThe editorial draws a parallel to the treatment of HIV, suggesting that while we may not see a 'magic bullet,' we are entering a 'golden age' of incremental progress. The ability to target the Ras family of molecules represents a fundamental shift in oncology, allowing for the treatment of approximately 40% of colorectal cancers and 30% of small-cell lung cancers. This underscores the growing importance of routine genetic screening to identify patients who will benefit from these precision therapies.The Future Outlook: A Golden Age of Incremental ProgressThe Guardian predicts that cancer will increasingly be managed as a chronic condition rather than a terminal one. With survival rates in the UK having doubled since the 1970s, the focus is shifting from seeking a sudden, total cure to securing more remissions and extending the quality of life for patients through continuous advancements in detection and drug development.

The Breakthrough in Diabetes TreatmentA new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results published in The Lancet. The medication, retatrutide, represents a significant advancement in diabetes treatment by targeting multiple pathways simultaneously.The Science Behind Triple-Action TherapyThe triple hormone drug mimics three gut hormones that help control appetite, blood sugar and metabolism: GLP-1, GIP and glucagon. Unlike other diabetes medications such as Ozempic and Wegovy, which primarily target the GLP-1 pathway to suppress appetite, or Mounjaro, which contains GLP-1 plus GIP to control blood-sugar levels, retatrutide also engages the glucagon receptor, which helps increase energy expenditure. This comprehensive approach addresses multiple aspects of metabolic dysfunction simultaneously.Impressive Clinical Trial ResultsIn the trial, 930 adults with type 2 diabetes were randomly assigned to receive 4mg, 9mg or 12mg of retatrutide, or placebo. After 40 weeks, the results were striking:The average drop in HbA1c was about 1.7-1.9 percentage points for participants receiving retatrutide, compared with 0.8 with the placeboParticipants lost on average about 11.5% to 15.3% of body weight on retatrutide, versus 2.6% with the placeboCholesterol and blood pressure also improved for those on the drugFourteen participants experienced serious adverse events during the trial, including two in the placebo group, but for most participants, side-effects were mild to moderate and eased with time, with gastrointestinal symptoms the most commonly experienced.Transforming Diabetes ManagementThe findings represent a potential paradigm shift in type 2 diabetes treatment. Dr Kath McCullough, special adviser on obesity at the Royal College of Physicians, noted that "for many people living with diabetes and obesity, treatments like this could be genuinely life-changing."Dr Lucy Chambers, head of research impact and communications at Diabetes UK, added: "These encouraging findings show that this new class of drug for type 2 diabetes could deliver dual benefits for both weight loss and blood-sugar management."However, experts caution that medications are not a silver bullet. Dr McCullough emphasized that "the long-term goal must be to prevent people from needing them in the first place."Future Directions and Comparative ResearchWhile the results are promising, Dr Marie Spreckley from IMS Epidemiology, University of Cambridge, pointed out that because this study compared retatrutide with placebo rather than existing medications like semaglutide or tirzepatide, direct head-to-head trials will be required to determine comparative effectiveness.Further clinical trials are continuing, with the manufacturer Eli Lilly also reporting positive results for retatrutide in reducing weight among patients with obesity. As research progresses, the medical community will gain a clearer understanding of where this triple-action therapy fits within the evolving landscape of diabetes and obesity treatments.

Podcast Overview: Red‑Light Masks and Ageing ClaimsThe Guardian’s latest science podcast asks the question, “Is it true that red‑light therapy masks prevent wrinkles?” It invites listeners to explore the evidence behind a popular anti‑ageing gadget.What the Episode CoversIntroduction to red‑light therapy and its purported skin‑benefits.Interviews with dermatologists and researchers discussing clinical findings.Consumer perspectives on the rise of at‑home light‑mask devices.Current Evidence LandscapeWhile some small studies suggest modest improvements in skin texture, the podcast notes the lack of large‑scale, peer‑reviewed trials confirming long‑term wrinkle reduction.Implications for Consumers and the Beauty IndustryThe discussion highlights a growing market for home‑use light devices, prompting regulators to consider clearer labelling and efficacy standards.Looking Ahead: Research and RegulationFuture episodes may track upcoming clinical trials and potential guidance from health authorities on the safe use of red‑light masks.